title: The importance of endoscopic ultrasonography in the management of low-grade gastric mucosa-associated lymphoid tissue lymphoma.
abstract: BACKGROUND
  Anti-Helicobacter pylori therapy has been reported to cause regression of low-grade gastric mucosa-associated lymphoid tissue lymphoma in a high percentage of patients. However, in some patients, these lesions persist despite antibiotic treatment.
  
  
  OBJECTIVE
  To determine the various endosonographic findings that may predict the regression of low-grade gastric mucosa-associated lymphoid tissue lymphoma post-antibiotics.
  
  
  METHODS
  Seventy-six patients with Helicobacter pylori-positive gastric mucosa-associated lymphoid tissue lymphoma were studied. Follow-up data were available on 51 patients. All patients were treated with antibiotics. Participants underwent pre- and post-anti-Helicobacter pylori therapy endoscopy with gastric biopsies, followed by endoscopic ultrasonography examination of the stomach.
  
  
  RESULTS
  Helicobacter pylori was eradicated in 45 of 51 (88%) patients. At the 2-year follow-up, complete regression of mucosa-associated lymphoid tissue lymphoma was seen in 28 of 51 (55%) patients: 12 of 16 (75%) patients in stage T1m N0, 11 of 19 (58%) patients in stage T1sm N0, four of eight (50%) patients in stages T1m N1 and T1sm N1, and one of four (25%) patients in stage T2 N0. None of the stage T2 N1 patients achieved clinical regression.
  
  
  CONCLUSIONS
  Endoscopic ultrasonography evaluation of gastric mucosa-associated lymphoid tissue lymphoma plays a pivotal role in the initial staging and post-treatment follow-up evaluation of these lesions. Accurate staging is essential in the determination of the optimal treatment modality.
authors.affiliation: Department of Internal Medicine and Gastroenterology, University of Bologna, Italy. g.caletti@ausl.imola.bo.it
authors.forename: G
authors.initials: G
authors.lastname: Caletti
authors.forename: P L
authors.initials: PL
authors.lastname: Zinzani
authors.forename: P
authors.initials: P
authors.lastname: Fusaroli
authors.forename: E
authors.initials: E
authors.lastname: Buscarini
authors.forename: F
authors.initials: F
authors.lastname: Parente
authors.forename: T
authors.initials: T
authors.lastname: Federici
authors.forename: S
authors.initials: S
authors.lastname: Peyre
authors.forename: C
authors.initials: C
authors.lastname: De Angelis
authors.forename: G
authors.initials: G
authors.lastname: Bonanno
authors.forename: T
authors.initials: T
authors.lastname: Togliani
authors.forename: S
authors.initials: S
authors.lastname: Pileri
authors.forename: S
authors.initials: S
authors.lastname: Tura
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D019160:Endosonography; D005260:Female; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy; D016480:Helicobacter pylori; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000000981:diagnostic imaging* / Q000382:microbiology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D013274:Stomach Neoplasms / Q000000981:diagnostic imaging* / Q000382:microbiology / Q000473:pathology
chemical_list: D000900:Anti-Bacterial Agents